Background {#Sec1}
==========

Major lower limb orthopedic surgery---such as total knee arthroplasty (TKA), total hip arthroplasty (THA), and hip fracture surgery (HFS)---is a significant risk factor for postoperative venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE) \[[@CR1], [@CR2]\]. For patients undergoing lower limb orthopedic surgery, several pharmacological and mechanical therapies are available for the prevention of VTE, including graduated compression stockings (GCS), which are a convenient and inexpensive mechanical prophylaxis measure \[[@CR1]\]. Although the exact mechanism of action of GCS remains unclear, they are believed to reduce the total cross-sectional area of the leg veins, thereby increasing venous blood flow velocity and preventing venous stasis in the lower limbs \[[@CR3]\].

Guidelines from the Japanese Circulation Society recommend the use of GCS for prophylaxis among patients at an intermediate risk for VTE \[[@CR1]\]. Anticoagulation or intermittent pneumatic compression (IPC) is recommended for patients at a high risk for VTE, such as those undergoing major orthopedic surgery, while anticoagulation plus IPC or GCS is recommended for patients at the highest risk for VTE \[[@CR1]\]. However, the efficacy of the combined treatment of anticoagulation with GCS relative to anticoagulation alone for VTE prevention among patients undergoing major lower limb orthopedic surgery has not been evaluated. In this study, an exploratory analysis was performed to evaluate the efficacy of GCS combined with enoxaparin or edoxaban, a direct, oral, factor Xa inhibitor, using data from a phase 3 clinical study that assessed the efficacy and safety of edoxaban (vs enoxaparin) for the prevention of postoperative VTE in patients undergoing TKA.

Methods {#Sec2}
=======

Study selection {#Sec3}
---------------

Three phase 3 studies involving patients undergoing TKA (TKA P3; STARS E-3 trial) \[[@CR4]\], THA (THA P3; STARS J-5 trial) \[[@CR5]\], or HFS (HFS P3; STARS J-4 trial) \[[@CR6]\] were considered for inclusion in this analysis. A total of 716, 610, and 92 patients were enrolled in the TKA P3 \[[@CR4]\], THA P3 \[[@CR5]\], and HFS P3 \[[@CR6]\] studies, respectively, of whom 594, 503, and 73, respectively, were evaluable for efficacy. These 3 studies were conducted between October 2008 and January 2010. In all 3 studies, the concomitant use of any method of mechanical prophylaxis, including GCS and IPC, was permitted. Table [1](#Tab1){ref-type="table"} summarizes the number of patients available for efficacy analysis stratified by the method of mechanical prophylaxis. Since there were few patients without mechanical prophylaxis in the THA P3 (1 patient) and HFS P3 (9 patients) studies, these 2 studies were excluded from the present analysis. In TKA P3, 129 patients received GCS alone as mechanical prophylaxis and 104 patients had no mechanical prophylaxis. Data from the TKA P3 study were included in the present analysis.Table 1Use of mechanical prophylaxis (efficacy analysis set)Mechanical prophylaxisTKA P3 *N* = 594THA P3 *N* = 503HFS P3 *N* = 73 GCSIPC ox12913639 oo23827415 xo1239210 xx10419*GCS* graduated compression stockings, *HFS P3* hip fracture surgery phase 3 study, *IPC* intermittent pneumatic compression, *THA P3* total hip arthroplasty phase 3 study, *TKA P3* total knee arthroplasty phase 3 studyo = patients receiving indicated treatment; x = patients without the indicated treatment

Study design and site selection {#Sec4}
-------------------------------

TKA P3 was a randomized, double-blind, parallel-group study performed by the double-dummy method (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR4]\]. Edoxaban (30 mg) was administered orally once a day, while enoxaparin (20 mg) was injected subcutaneously twice a day for 11 to 14 days in accordance with standard practice. Edoxaban was administered 6 to 24 h after surgery, whereas enoxaparin treatment commenced 24 to 36 h following surgery. Venography was performed within 24 h after the last dose, and occurrence of VTE was determined by an independent Clinical Event Committee that was blinded to the treatment of the patients. The primary efficacy endpoint was the percentage of patients who developed asymptomatic DVT, symptomatic DVT, or symptomatic PE (the incidence of VTE).Fig. 1Study design (phase 3 total knee arthroplasty study) \[[@CR4]\]. ^a^Treatment with oral edoxaban commenced 6--24 h postoperatively. ^b^Treatment with subcutaneous enoxaparin commenced 24--36 h postoperatively. ^c^Follow-up occurred 25--35 days after the last administered dose

In TKA P3, 716 patients were enrolled at 71 sites. To exclude possible bias due to selection of GCS depending on the severity of illness or the VTE risk of each patient, 18 sites where GCS had been used for selected patients were excluded from the present analysis. Thus, the remaining 422 patients from 53 sites were considered for inclusion in the present analysis. To avoid the influence of other mechanical methods (eg, IPC), patients who had also used IPC were excluded as well. Thus, the present analysis compared 101 patients who had used GCS alone as mechanical prophylaxis (53 from the edoxaban group and 48 from the enoxaparin group) with 100 patients without any mechanical prophylaxis (52 from the edoxaban group and 48 from the enoxaparin group), so a total of 201 patients were included in this assessment of the efficacy of GCS.

Statistical analysis {#Sec5}
--------------------

The incidence of VTE was summarized using descriptive statistics. Treatment comparisons were made using the *χ*2 test and the 95 % confidence interval was calculated.

Results {#Sec6}
=======

The demographics and baseline characteristics of patients included in this subanalysis are presented in Table [2](#Tab2){ref-type="table"}. The mean age, body weight, and creatinine clearance were not different among patients regardless of anticoagulant and/or mechanical prophylaxis use. Tourniquet use was lower, whereas the use of epidural and lumbar anesthesia was higher among patients receiving GCS relative to those without any mechanical prophylaxis. This difference was due to facility-specific practices; facilities employing GCS for prophylaxis had lower rates of tourniquet or general anesthesia use. Mean GCS use was 9.5 and 9.6 days for the edoxaban and enoxaparin groups, respectively. The mean (standard deviation) time interval between surgery and the start of postoperative anticoagulant therapy was 20 h and 7 min (2 h and 50 min) for the edoxaban group and 28 h and 54 min (3 h and 29 min) for the enoxaparin group. Enoxaparin was administered between 24 to 36 h after surgery, in accordance with enoxaparin prescribing practices \[[@CR7]\], accounting for this difference in initiation of anticoagulation following surgery.Table 2Demographic and baseline characteristics summaryDemographic and other baseline characteristicsNo mechanical prophylaxisGCS alone*N* = 100*N* = 101EdoxabanEnoxaparinEdoxabanEnoxaparin*N* = 52*N* = 48*N* = 53*N* = 48Sex, n (%) Male11 (21.2)9 (18.8)8 (15.1)9 (18.8) Female41 (78.8)39 (81.3)45 (84.9)39 (81.3)Age, (y) Mean ± SD70.9 ± 7.971.7 ± 7.873.5 ± 6.173.2 ± 7.0Weight, (kg) Mean ± SD63.2 ± 10.264.3 ± 11.956.8 ± 10.260.3 ± 10.1CL~cr~, (mL/min) Mean ± SD78.3 ± 24.676.2 ± 26.571.1 ± 20.174.9 ± 20.0Duration of surgery, (h:min) Mean ± SD2:03 ± 0:441:59 ± 0:351:42 ± 0:261:45 ± 0:24Tourniquet use during surgery, n (%)50 (96.2)46 (95.8)42 (79.2)38 (79.2)Method of anesthesia, n (%) General anesthesia43 (82.7)35 (72.9)24 (45.3)20 (41.7) Epidural anesthesia8 (15.4)7 (14.6)17 (32.1)14 (29.2) Lumbar anesthesia24 (46.2)24 (50.0)38 (71.7)34 (70.8)Duration from the end of surgery to the start of anticoagulation, (h:min) Mean ± SD20:31 ± 2:3930:41 ± 3:2619:43 ± 2:5927:08 ± 2:30Duration from surgery to ambulation (days) Mean ± SD2.2 ± 0.72.4 ± 0.83.6 ± 1.43.8 ± 2.1Duration of treatment (days) Mean ± SD12.1 ± 1.611.6 ± 2.612.4 ± 1.612.4 ± 1.7Duration of GCS use (days) Mean ± SD\--9.5 ± 2.79.6 ± 2.7*CL* ~*cr*~ creatinine clearance, *GCS* graduated compression stockings, *SD* standard deviation

In the edoxaban group, the incidence of VTE was 3.8 % (2/53) and 5.8 % (3/52) for patients with and without GCS mechanical prophylaxis, respectively (*p* = 0.6312; Table [3](#Tab3){ref-type="table"}). In the enoxaparin group, the incidence of VTE was 8.4 % (4/48) for patients using GCS alone as mechanical prophylaxis, and 20.8 % (10/48) for patients without mechanical prophylaxis (*p* = 0.0827). Combining the 2 groups, the incidence of VTE was 6.0 % (6/101) and 13.0 % (13/100) for patients with and without GCS mechanical prophylaxis. There were no deaths in this study. Of the 201 patients included in this analysis, no instances of symptomatic or asymptomatic PE and no instances of symptomatic DVT were observed; all patients had asymptomatic DVT.Table 3Incidence of VTE^a^ in patients using GCS for prophylaxisEdoxabanEnoxaparinTotal*N* = 105*N* = 96*N* = 201No mechanical prophylaxis5.8 % (3/52)20.8 % (10/48)13.0 % (13/100)Mechanical prophylaxis with GCS alone3.8 % (2/53)8.4 % (4/48)6.0 % (6/101)Chi-square test*p* = 0.6312*p* = 0.0827*p* = 0.0872Difference between with and without GCS treatment groups--2.0--12.5--7.195 % CI of the difference shown by the score test−12.2, 7.8−26.8, 1.9−15.7, 1.2*CI* confidence interval, *GCS* graduated compression stockings, *VTE* venous thromboembolism^a^All instances of VTE were asymptomatic DVT; no instances of symptomatic or asymptomatic PE or symptomatic DVT were observed

Discussion {#Sec7}
==========

Anticoagulants prevent VTE by suppressing hypercoagulability \[[@CR8]\], while GCS prevent VTE by increasing the venous blood flow velocity and impeding venous stasis in the legs \[[@CR3]\]. Thus, 2 independent elements of Virchow's thrombogenic triad ("hypercoagulability" and "venous stasis") \[[@CR8]\] are targeted when prophylaxis with anticoagulant therapy and GCS is combined. This is thought to be the mechanism by which combined therapy achieves a greater reduction in the incidence of VTE after major lower limb orthopedic surgery. Few studies have examined the efficacy of combined anticoagulant and GCS therapy relative to anticoagulation alone for VTE prevention among patients undergoing major orthopedic surgery \[[@CR9]\]. A study involving patients undergoing THA in the UK revealed that the incidence of DVT or PE was not significantly different between patients receiving enoxaparin plus GCS compared to those receiving enoxaparin alone \[[@CR10]\]. However, this study was limited by its small sample size, with 32 patients randomized to each treatment group \[[@CR10]\]. Among Swedish patients undergoing THA, combined treatment with dextran (infused at anesthesia and for 2 days following surgery) and GCS was more effective for postoperative DVT prevention than treatment with dextran alone \[[@CR11]\].

Although Japanese guidelines recommend the use of GCS with anticoagulation for prophylaxis among patients at the highest risk for VTE \[[@CR1]\], the efficacy of this combined treatment relative to anticoagulation alone for Japanese patients undergoing major orthopedic surgery has previously not been reported. The findings from the present study suggest that concomitant treatment with anticoagulation and GCS resulted in a \>2-fold reduction in VTE incidence relative to anticoagulation alone among Japanese patients undergoing TKA, although this difference was not statistically significant. Addition of GCS therapy led to a numerically greater reduction in VTE incidence primarily among patients receiving enoxaparin, while this reduction was less pronounced among those receiving edoxaban. This difference may have arisen partly because edoxaban was started earlier in the postoperative period; as a result, there was a smaller margin for further reduction of VTE occurrence with the addition of GCS among patients treated with edoxaban. Given the limited number of patients in this analysis (*n* = 201), and the delay in the initiation of anticoagulation with enoxaparin relative to edoxaban, these exploratory results need to be confirmed in larger, prospective, randomized trials.

Conclusion {#Sec8}
==========

To evaluate the efficacy of GCS for prevention of VTE, an exploratory analysis was performed by using data from a phase 3 clinical study of postoperative prophylaxis with edoxaban vs enoxaparin in patients undergoing TKA. The results of the analysis suggested that the occurrence of VTE was numerically lower among patients receiving anticoagulant plus GCS therapy relative to those receiving anticoagulation alone, although this difference was not statistically significant. Further studies are required to confirm the findings of this preliminary analysis. Additionally, due to the limitations of this analysis, further studies need to be performed to evaluate the relative prophylactic efficacy of combined anticoagulant and GCS therapy compared with anticoagulation alone.
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